BioSante Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Lincolnshire, Illinois (December 5, 2007) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Michael Snabes, its medical director, will be presenting a LibiGel® (transdermal testosterone gel) poster at a meeting of the Sexual Medicine Society of North America (SMSNA) at the Westin Chicago River North on Sunday December 9, 2007. The SMSNA fall meeting is attended by practitioners and scientists and is a dynamic scientific meeting with presentations on basic science and clinical developments in the area of sexual medicine.
In addition, Stephen M. Simes, the company’s president and chief executive officer, will present a corporate update and overview at the New York Society of Security Analyst’s (NYSSA) Annual Biotech/Specialty Pharma Conference in New York City. Mr. Simes will present on December 11, 2007 at 11:30 a.m. local time. The NYSSA conference is attended by brokers and fund managers and features the CEOs and CFOs from many of the industry’s most innovative small-and micro-cap companies discussing their plans to develop and commercialize important new drugs, diagnostics and delivery technologies.
A live audio webcast of BioSante’s presentation at the NYSSA conference may be accessed. A replay will be available at the same link for 90 days.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante’s lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S.by Bradley Pharmaceuticals, Inc., BioSante’s licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD).
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine (BioLook™). Additional information is available online at www.biosantepharma.com.
For more information please contact:
Harris D. McKinney, Inc.